Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 51 entries
Sorted by: Best Match Show Resources per page
The need for biodiversity champions in psychiatry: the entwined crises of climate change and ecological collapse.

BJPsych bulletin

Krzanowski J.
PMID: 34103120
BJPsych Bull. 2021 Aug;45(4):238-243. doi: 10.1192/bjb.2021.44.

SUMMARY: The past 20 years have seen the disappearance and degradation of biodiversity on earth at unprecedented rates. This phenomenon shares similar drivers to those behind climate change yet requires its own solutions. The twin catastrophes of climate change...

Cite
Krzanowski J. The need for biodiversity champions in psychiatry: the entwined crises of climate change and ecological collapse. BJPsych Bull. 2021;45(4):238-243doi: 10.1192/bjb.2021.44.
Krzanowski, J. (2021). The need for biodiversity champions in psychiatry: the entwined crises of climate change and ecological collapse. BJPsych bulletin, 45(4), 238-243. https://doi.org/10.1192/bjb.2021.44
Krzanowski, Jacob. "The need for biodiversity champions in psychiatry: the entwined crises of climate change and ecological collapse." BJPsych bulletin vol. 45,4 (2021): 238-243. doi: https://doi.org/10.1192/bjb.2021.44
Krzanowski J. The need for biodiversity champions in psychiatry: the entwined crises of climate change and ecological collapse. BJPsych Bull. 2021 Aug;45(4):238-243. doi: 10.1192/bjb.2021.44. PMID: 34103120; PMCID: PMC8499615.
Copy Download .nbib Format: NLM
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG.
PMID: 34570655
J Clin Oncol. 2021 Nov 20;39(33):3716-3724. doi: 10.1200/JCO.21.00920. Epub 2021 Sep 27.

PURPOSE: A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective...

Cite
Burke GAA, Minard-Colin V, Aupérin A, et al. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. J Clin Oncol. 2021;39(33):3716-3724doi: 10.1200/JCO.21.00920.
Burke, G. A. A., Minard-Colin, V., Aupérin, A., Alexander, S., Pillon, M., Delgado, R., Zsíros, J., Uyttebroeck, A., Dartigues, P., Miles, R. R., Kazanowska, B., Chiang, A. K., Haouy, S., Bollard, C. M., Csoka, M., Wheatley, K., Barkauskas, D. A., Adamson, P. C., Vassal, G., Patte, C., & Gross, T. G. (2021). Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(33), 3716-3724. https://doi.org/10.1200/JCO.21.00920
Burke, G A Amos, et al. "Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,33 (2021): 3716-3724. doi: https://doi.org/10.1200/JCO.21.00920
Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. J Clin Oncol. 2021 Nov 20;39(33):3716-3724. doi: 10.1200/JCO.21.00920. Epub 2021 Sep 27. PMID: 34570655.
Copy Download .nbib Format: NLM
Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation.

Postepy dermatologii i alergologii

Sułowicz J, Wojas-Pelc A, Ignacak E, Krzanowska K, Kuźniewski M, Sułowicz W.
PMID: 28507493
Postepy Dermatol Alergol. 2017 Apr;34(2):138-142. doi: 10.5114/ada.2017.67078. Epub 2017 Apr 13.

INTRODUCTION: Kidney transplant (KTx) patients on immunosuppressive therapy are predisposed to the development of infections and cancers.AIM: To compare the incidence and type of malignant skin lesions in kidney transplant patients and the dialyzed population based on the initiated...

Cite
Sułowicz J, Wojas-Pelc A, Ignacak E, et al. Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation. Postepy Dermatol Alergol. 2017;34(2):138-142doi: 10.5114/ada.2017.67078.
Sułowicz, J., Wojas-Pelc, A., Ignacak, E., Krzanowska, K., Kuźniewski, M., & Sułowicz, W. (2017). Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation. Postepy dermatologii i alergologii, 34(2), 138-142. https://doi.org/10.5114/ada.2017.67078
Sułowicz, Joanna, et al. "Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation." Postepy dermatologii i alergologii vol. 34,2 (2017): 138-142. doi: https://doi.org/10.5114/ada.2017.67078
Sułowicz J, Wojas-Pelc A, Ignacak E, Krzanowska K, Kuźniewski M, Sułowicz W. Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation. Postepy Dermatol Alergol. 2017 Apr;34(2):138-142. doi: 10.5114/ada.2017.67078. Epub 2017 Apr 13. PMID: 28507493; PMCID: PMC5420606.
Copy Download .nbib Format: NLM
Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials.

Pediatric blood & cancer

Seitz G, Urla C, Sparber-Sauer M, Schuck A, Vokuhl C, Blank B, Klingebiel T, Kazanowska B, Fuchs J, Koscielniak E.
PMID: 31393080
Pediatr Blood Cancer. 2019 Aug;66:e27884. doi: 10.1002/pbc.27884.

BACKGROUND: Ewing tumors are the most frequent malignant tumors of the chest wall in children and young adults. Surgical management of these tumors can be challenging. Optimal local control remains controversial. The aim of this study was to analyze...

Cite
Seitz G, Urla C, Sparber-Sauer M, et al. Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials. Pediatr Blood Cancer. 2019;66:e27884doi: 10.1002/pbc.27884.
Seitz, G., Urla, C., Sparber-Sauer, M., Schuck, A., Vokuhl, C., Blank, B., Klingebiel, T., Kazanowska, B., Fuchs, J., & Koscielniak, E. (2019). Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials. Pediatric blood & cancer, 66e27884. https://doi.org/10.1002/pbc.27884
Seitz, Guido, et al. "Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials." Pediatric blood & cancer vol. 66 (2019): e27884. doi: https://doi.org/10.1002/pbc.27884
Seitz G, Urla C, Sparber-Sauer M, Schuck A, Vokuhl C, Blank B, Klingebiel T, Kazanowska B, Fuchs J, Koscielniak E. Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials. Pediatr Blood Cancer. 2019 Aug;66:e27884. doi: 10.1002/pbc.27884. PMID: 31393080.
Copy Download .nbib Format: NLM
New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.

Journal of clinical medicine

Banaszkiewicz M, Małyszko J, Vesole DH, Woziwodzka K, Jurczyszyn A, Żórawski M, Krzanowski M, Małyszko J, Batko K, Kuźniewski M, Krzanowska K.
PMID: 31683939
J Clin Med. 2019 Nov 01;8(11). doi: 10.3390/jcm8111828.

Multiple myeloma (MM) is a malignancy of clonal plasma cells accounting for approximately 10% of haematological malignancies. MM mainly affects older patients, more often males and is more frequently seen in African Americans. The most frequent manifestations of MM...

Cite
Banaszkiewicz M, Małyszko J, Vesole DH, et al. New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. J Clin Med. 2019;8(11)doi: 10.3390/jcm8111828.
Banaszkiewicz, M., Małyszko, J., Vesole, D. H., Woziwodzka, K., Jurczyszyn, A., Żórawski, M., Krzanowski, M., Małyszko, J., Batko, K., Kuźniewski, M., & Krzanowska, K. (2019). New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. Journal of clinical medicine, 8(11), . https://doi.org/10.3390/jcm8111828
Banaszkiewicz, Małgorzata, et al. "New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia." Journal of clinical medicine vol. 8,11 (2019). doi: https://doi.org/10.3390/jcm8111828
Banaszkiewicz M, Małyszko J, Vesole DH, Woziwodzka K, Jurczyszyn A, Żórawski M, Krzanowski M, Małyszko J, Batko K, Kuźniewski M, Krzanowska K. New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. J Clin Med. 2019 Nov 01;8(11). doi: 10.3390/jcm8111828. PMID: 31683939; PMCID: PMC6912471.
Copy Download .nbib Format: NLM
Triarylisocyanurate-Based Fluorescent Two-Photon Absorbers.

ChemPlusChem

Gautier Y, Argouarch G, Malvolti F, Blondeau B, Richy N, Amar A, Boucekkine A, Nawara K, Chlebowicz K, Orzanowska G, Dudek M, Matczyszyn K, Samoc M, Blanchard-Desce M, Mongin O, Waluk J, Paul F.
PMID: 32119196
Chempluschem. 2020 Mar;85(3):411-425. doi: 10.1002/cplu.202000036.

The synthesis and characterization of six triarylisocyanurates, featuring 2,7-fluorenyl or 9,10-anthracenyl groups incorporated in their peripheral arms are reported. Photophysical studies reveal that these new octupolar derivatives are more fluorescent (Φ

Cite
Gautier Y, Argouarch G, Malvolti F, et al. Triarylisocyanurate-Based Fluorescent Two-Photon Absorbers. Chempluschem. 2020;85(3):411-425doi: 10.1002/cplu.202000036.
Gautier, Y., Argouarch, G., Malvolti, F., Blondeau, B., Richy, N., Amar, A., Boucekkine, A., Nawara, K., Chlebowicz, K., Orzanowska, G., Dudek, M., Matczyszyn, K., Samoc, M., Blanchard-Desce, M., Mongin, O., Waluk, J., & Paul, F. (2020). Triarylisocyanurate-Based Fluorescent Two-Photon Absorbers. ChemPlusChem, 85(3), 411-425. https://doi.org/10.1002/cplu.202000036
Gautier, Yohan, et al. "Triarylisocyanurate-Based Fluorescent Two-Photon Absorbers." ChemPlusChem vol. 85,3 (2020): 411-425. doi: https://doi.org/10.1002/cplu.202000036
Gautier Y, Argouarch G, Malvolti F, Blondeau B, Richy N, Amar A, Boucekkine A, Nawara K, Chlebowicz K, Orzanowska G, Dudek M, Matczyszyn K, Samoc M, Blanchard-Desce M, Mongin O, Waluk J, Paul F. Triarylisocyanurate-Based Fluorescent Two-Photon Absorbers. Chempluschem. 2020 Mar;85(3):411-425. doi: 10.1002/cplu.202000036. PMID: 32119196.
Copy Download .nbib Format: NLM
Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring .

Oncotarget

Pastorczak A, Sedek L, Braun M, Madzio J, Sonsala A, Twardoch M, Fendler W, Nebral K, Taha J, Bielska M, Gorniak P, Romiszewska M, Matysiak M, Derwich K, Lejman M, Kowalczyk J, Badowska W, Niedzwiecki M, Kazanowska B, Muszynska-Roslan K, Sobol-Milejska G, Karolczyk G, Koltan A, Ociepa T, Szczepanski T, Młynarski W.
PMID: 29899835
Oncotarget. 2018 May 25;9(40):25971-25982. doi: 10.18632/oncotarget.25411. eCollection 2018 May 25.

We prospectively examined whether surface expression of Cytokine Receptor-Like Factor 2 (CRLF2) on leukemic blasts is associated with survival and induction treatment response in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Flow cytometric analysis of bone marrow-derived leukemia...

Cite
Pastorczak A, Sedek L, Braun M, et al. Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring . Oncotarget. 2018;9(40):25971-25982doi: 10.18632/oncotarget.25411.
Pastorczak, A., Sedek, L., Braun, M., Madzio, J., Sonsala, A., Twardoch, M., Fendler, W., Nebral, K., Taha, J., Bielska, M., Gorniak, P., Romiszewska, M., Matysiak, M., Derwich, K., Lejman, M., Kowalczyk, J., Badowska, W., Niedzwiecki, M., Kazanowska, B., Muszynska-Roslan, K., Sobol-Milejska, G., Karolczyk, G., Koltan, A., Ociepa, T., Szczepanski, T., & Młynarski, W. (2018). Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring . Oncotarget, 9(40), 25971-25982. https://doi.org/10.18632/oncotarget.25411
Pastorczak, Agata, et al. "Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring ." Oncotarget vol. 9,40 (2018): 25971-25982. doi: https://doi.org/10.18632/oncotarget.25411
Pastorczak A, Sedek L, Braun M, Madzio J, Sonsala A, Twardoch M, Fendler W, Nebral K, Taha J, Bielska M, Gorniak P, Romiszewska M, Matysiak M, Derwich K, Lejman M, Kowalczyk J, Badowska W, Niedzwiecki M, Kazanowska B, Muszynska-Roslan K, Sobol-Milejska G, Karolczyk G, Koltan A, Ociepa T, Szczepanski T, Młynarski W. Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring . Oncotarget. 2018 May 25;9(40):25971-25982. doi: 10.18632/oncotarget.25411. eCollection 2018 May 25. PMID: 29899835; PMCID: PMC5995260.
Copy Download .nbib Format: NLM
New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies.

Journal of clinical medicine

Woziwodzka K, Vesole DH, Małyszko J, Batko K, Jurczyszyn A, Koc-Żórawska E, Krzanowski M, Małyszko J, Żórawski M, Waszczuk-Gajda A, Kuźniewski M, Krzanowska K.
PMID: 32486490
J Clin Med. 2020 May 31;9(6). doi: 10.3390/jcm9061652.

No abstract available.

Cite
Woziwodzka K, Vesole DH, Małyszko J, et al. New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. J Clin Med. 2020;9(6)doi: 10.3390/jcm9061652.
Woziwodzka, K., Vesole, D. H., Małyszko, J., Batko, K., Jurczyszyn, A., Koc-Żórawska, E., Krzanowski, M., Małyszko, J., Żórawski, M., Waszczuk-Gajda, A., Kuźniewski, M., & Krzanowska, K. (2020). New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. Journal of clinical medicine, 9(6), . https://doi.org/10.3390/jcm9061652
Woziwodzka, Karolina, et al. "New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies." Journal of clinical medicine vol. 9,6 (2020). doi: https://doi.org/10.3390/jcm9061652
Woziwodzka K, Vesole DH, Małyszko J, Batko K, Jurczyszyn A, Koc-Żórawska E, Krzanowski M, Małyszko J, Żórawski M, Waszczuk-Gajda A, Kuźniewski M, Krzanowska K. New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. J Clin Med. 2020 May 31;9(6). doi: 10.3390/jcm9061652. PMID: 32486490; PMCID: PMC7355449.
Copy Download .nbib Format: NLM
Selected miRNA levels are associated with .

Oncology letters

Krzanowski J, Madzio J, Pastorczak A, Tracz A, Braun M, Tabarkiewicz J, Pluta A, Młynarski W, Zawlik I.
PMID: 28927157
Oncol Lett. 2017 Sep;14(3):3853-3861. doi: 10.3892/ol.2017.6599. Epub 2017 Jul 18.

The clinical outcome of children with high-risk relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is poor. The present study assessed the utility and prognostic value of selected microRNA (miRNA/miR) in BCP-ALL. The changes in the expression levels of these...

Cite
Krzanowski J, Madzio J, Pastorczak A, et al. Selected miRNA levels are associated with . Oncol Lett. 2017;14(3):3853-3861doi: 10.3892/ol.2017.6599.
Krzanowski, J., Madzio, J., Pastorczak, A., Tracz, A., Braun, M., Tabarkiewicz, J., Pluta, A., Młynarski, W., & Zawlik, I. (2017). Selected miRNA levels are associated with . Oncology letters, 14(3), 3853-3861. https://doi.org/10.3892/ol.2017.6599
Krzanowski, J, et al. "Selected miRNA levels are associated with ." Oncology letters vol. 14,3 (2017): 3853-3861. doi: https://doi.org/10.3892/ol.2017.6599
Krzanowski J, Madzio J, Pastorczak A, Tracz A, Braun M, Tabarkiewicz J, Pluta A, Młynarski W, Zawlik I. Selected miRNA levels are associated with . Oncol Lett. 2017 Sep;14(3):3853-3861. doi: 10.3892/ol.2017.6599. Epub 2017 Jul 18. PMID: 28927157; PMCID: PMC5588016.
Copy Download .nbib Format: NLM
Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia.

Postepy dermatologii i alergologii

Kupryś-Lipińska I, Kołacińska-Flont M, Marczak J, Górski P, Kurmanowska Z, Kuna P.
PMID: 26755915
Postepy Dermatol Alergol. 2015 Dec;32(6):478-9. doi: 10.5114/pdia.2015.48072. Epub 2015 Dec 11.

No abstract available.

Cite
Kupryś-Lipińska I, Kołacińska-Flont M, Marczak J, et al. Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia. Postepy Dermatol Alergol. 2015;32(6):478-9doi: 10.5114/pdia.2015.48072.
Kupryś-Lipińska, I., Kołacińska-Flont, M., Marczak, J., Górski, P., Kurmanowska, Z., & Kuna, P. (2015). Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia. Postepy dermatologii i alergologii, 32(6), 478-9. https://doi.org/10.5114/pdia.2015.48072
Kupryś-Lipińska, Izabela, et al. "Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia." Postepy dermatologii i alergologii vol. 32,6 (2015): 478-9. doi: https://doi.org/10.5114/pdia.2015.48072
Kupryś-Lipińska I, Kołacińska-Flont M, Marczak J, Górski P, Kurmanowska Z, Kuna P. Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia. Postepy Dermatol Alergol. 2015 Dec;32(6):478-9. doi: 10.5114/pdia.2015.48072. Epub 2015 Dec 11. PMID: 26755915; PMCID: PMC4697022.
Copy Download .nbib Format: NLM
Exhaled breath 8-isoprostane as a marker of asthma severity.

Archives of medical science : AMS

Piotrowski WJ, Majewski S, Marczak J, Kurmanowska Z, Górski P, Antczak A.
PMID: 22852009
Arch Med Sci. 2012 Jul 04;8(3):515-20. doi: 10.5114/aoms.2012.28639.

INTRODUCTION: Oxidative stress is a non-specific feature of airway inflammation in asthmatics. 8-Isoprostane (8-IP), a prostaglandin-F(2α) isomer, is a relatively new marker of oxidative stress and may be measured in exhaled breath condensate (EBC) of patients with asthma. This...

Cite
Piotrowski WJ, Majewski S, Marczak J, et al. Exhaled breath 8-isoprostane as a marker of asthma severity. Arch Med Sci. 2012;8(3):515-20doi: 10.5114/aoms.2012.28639.
Piotrowski, W. J., Majewski, S., Marczak, J., Kurmanowska, Z., Górski, P., & Antczak, A. (2012). Exhaled breath 8-isoprostane as a marker of asthma severity. Archives of medical science : AMS, 8(3), 515-20. https://doi.org/10.5114/aoms.2012.28639
Piotrowski, Wojciech J, et al. "Exhaled breath 8-isoprostane as a marker of asthma severity." Archives of medical science : AMS vol. 8,3 (2012): 515-20. doi: https://doi.org/10.5114/aoms.2012.28639
Piotrowski WJ, Majewski S, Marczak J, Kurmanowska Z, Górski P, Antczak A. Exhaled breath 8-isoprostane as a marker of asthma severity. Arch Med Sci. 2012 Jul 04;8(3):515-20. doi: 10.5114/aoms.2012.28639. PMID: 22852009; PMCID: PMC3400897.
Copy Download .nbib Format: NLM
Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): exposing patients "hard work" of managing acute cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Haase KR, Avery J, Bryant-Lukosius D, Kryzanowska M, Kukretti V, Liu G, Mayo SJ, Jones J, Howell D.
PMID: 32829463
Support Care Cancer. 2021 Apr;29(4):1989-1998. doi: 10.1007/s00520-020-05683-8. Epub 2020 Aug 22.

PURPOSE: People with cancer benefit from self-management support, but report limitations in the type/amount of support they receive from healthcare professionals during cancer treatment. To intervene in this critical period, our team is developing a web-based self-management system, called...

Cite
Haase KR, Avery J, Bryant-Lukosius D, et al. Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): exposing patients "hard work" of managing acute cancer. Support Care Cancer. 2020;29(4):1989-1998doi: 10.1007/s00520-020-05683-8.
Haase, K. R., Avery, J., Bryant-Lukosius, D., Kryzanowska, M., Kukretti, V., Liu, G., Mayo, S. J., Jones, J., & Howell, D. (2021). Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): exposing patients "hard work" of managing acute cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(4), 1989-1998. https://doi.org/10.1007/s00520-020-05683-8
Haase, Kristen R, et al. "Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): exposing patients "hard work" of managing acute cancer." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 29,4 (2021): 1989-1998. doi: https://doi.org/10.1007/s00520-020-05683-8
Haase KR, Avery J, Bryant-Lukosius D, Kryzanowska M, Kukretti V, Liu G, Mayo SJ, Jones J, Howell D. Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): exposing patients "hard work" of managing acute cancer. Support Care Cancer. 2021 Apr;29(4):1989-1998. doi: 10.1007/s00520-020-05683-8. Epub 2020 Aug 22. PMID: 32829463.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 51 entries